London, 21 November 2017
Immodulon Therapeutics, a biopharmaceutical company engaged in the development of immunotherapy compounds, is pleased to announce the appointment of former ASDA CEO, Andy Clarke, as its Non- Executive Chairman. He will be joined by Dr. Jerome Zeldis, who is appointed as Executive Vice Chairman and Dr. Graham Burton as Chief Operating Officer. The appointments come at a time that marks a new phase in Immodulon’s development as an immuno-oncology company.
Business veteran Andy Clarke previously spent 20 years at leading supermarket ASDA, culminating in a six-year tenure as its CEO from May 2010 to June 2016. Andy has over 25 years’ experience of driving performance improvements in multi-brand international business in a diverse range of sectors, including food, fashion and general merchandise at property intensive, multi-channel and online retailers. He has managed businesses with a turnover of between £1b and £25b, and with net income ranging from £150m to £1.1b, and he was a member of the Prime Minister’s Business Advisory Group from 2015 – 2016.
Both Dr. Zeldis and Dr. Burton bring a wealth of pharmaceutical industry experience to Immodulon. Dr. Zeldis joins the company from Celgene where he held the position of Chief Medical Officer and CEO of Celgene Global Health. During his tenure the company grew into a leading global biopharmaceutical company. Throughout the most of his 19 years at Celgene, Dr. Zeldis was responsible for Celgene’s clinical research and medical affairs. He also supervised drug safety. During this period, Celgene brought 6 drugs to market.
Dr. Burton is a seasoned pharmaceutical executive with over 30 years of global experience in the pharmaceutical industry. He also joins Immodulon from Celgene where he held a variety of leadership roles, including Senior Vice President of Regulatory, Pharmacovigilance, and Clinical Quality from 2003 to 2013.
The Board appointments mark an important new phase in Immodulon’s ambition to establish itself as a leading independent player in the global market for immunotherapy, an exciting and clinically vital therapeutic class that has the potential to revolutionise the treatment of cancer.
Board Director Hugo Mackenzie Smith commented: “Andy Clarke is a highly capable and respected leader, and we are confident that his business acumen and retail sector experience will afford Immodulon with invaluable insight and a fresh perspective as it accelerates on its journey to market. Similarly, I have no doubt that Jerry and Graham’s wealth of experience and impressive track record at Celgene will support the progression of the continued clinical development and commercialisation of Immodulon’s lead immunotherapy compound, IMM-101.”
Andy Clarke commented: “Joining Immodulon represents an exciting shift in focus for me. I am looking forward to spearheading the development of a growing company looking to commercialise truly innovative products in the field of immunotherapy, and tackle some of the world’s deadliest illnesses. I am delighted to be supported in this endeavor by a highly experienced and well-established Board and management team, formed of leaders in their respective fields.”
Dr. Zeldis added “I am particularly pleased to be joining Immodulon which I see as one of the most exciting biopharmaceutical players in the industry. Immodulon’s portfolio of strong assets have yielded some impressive results to date and I am looking forward to the opportunity of building on these foundations to drive the clinical development of Immodulon’s world-class, unique immunotherapy compounds.”
- Andrew Orchard, Hawthorn Advisors: +44 (0) 20 3745 3817
- Flora Blackett-Ord, Hawthorn Advisors: +44 (0) 20 3745 4968
Notes to Editors
Immodulon Therapeutics [‘Immodulon’] is a clinical-stage independent biopharmaceutical company, engaged in the development of immunotherapy compounds, primarily for use as combination therapies in the treatment of cancer. Clinical trials have demonstrated that its headline compound IMM-101, a natural bacterial treatment which modulates the body’s immune response, can significantly enhance average survival rates in some of the deadliest cancers.
Founded in 2007, Immodulon has one of the longest running research projects into immunotherapy. Following successful Phase II trials in September 2016, the company is currently focused on investing in clinical development of IMM-101 to commercialise and ultimately bring to market this potentially transformational compound. The company is guided by a highly experienced board with both medical and commercial expertise, including City veterans Sir Simon Robertson and Anthony Bolton. Immodulon’s assets are strongly protected and the company has both development and manufacturing capabilities, creating a scalable and commercially viable proposition.